Loading…
Eikon Therapeutics, Inc. is projected to decline to $8.98 by 2027, a -13% move from its current price of $10.37. EIKN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $9.82 | $10.38 | $10.97 | +0.08% |
| May 30 | $9.60 | $10.39 | $11.24 | +0.17% |
| May 31 | $9.44 | $10.40 | $11.45 | +0.25% |
| Jun 1 | $9.31 | $10.40 | $11.63 | +0.33% |
| Jun 2 | $9.19 | $10.41 | $11.80 | +0.42% |
| Jun 3 | $9.09 | $10.42 | $11.95 | +0.50% |
| Jun 4 | $9.00 | $10.43 | $12.09 | +0.58% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.00 | $10.43 | $12.09 | +0.58% |
| Week 2 | $8.51 | $10.49 | $12.93 | +1.17% |
| Week 3 | $8.17 | $10.55 | $13.63 | +1.76% |
| Week 4 | $7.90 | $10.61 | $14.26 | +2.35% |
| Week 5 | $7.67 | $10.68 | $14.85 | +2.94% |
| Week 6 | $7.48 | $10.74 | $15.41 | +3.54% |
| Week 7 | $7.31 | $10.80 | $15.96 | +4.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company operating in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor.
The company was incorporated in 2019 and is based in Millbrae, California.
The asset is Eikon Therapeutics, Inc. (EIKN). The current price is $9.90. It has a market cap of $535.97M and a rank of 2989. The stock sits in the Healthcare category.
A major floor 41.8% below — a decisive break under it would weaken the trend.
The nearest floor, 17.5% below — buyers have tended to step in here.
The nearest ceiling, 27.8% above — a clean break opens room to run.
A major ceiling 56.8% above — clearing it would confirm fresh momentum.
Key EIKN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EIKN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.60 | Sell | $10.61 | Sell |
| MA 10 | $11.41 | Sell | $10.82 | Sell |
| MA 20 | $10.68 | Sell | $10.80 | Sell |
| MA 50 | $10.56 | Sell | $11.14 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.21 | Neutral |
| Stoch RSI (14) | 24.15 | Neutral |
| CCI (20) | -22.46 | Neutral |
| Williams %R (14) | -70.59 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | 4.12 | Buy |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 29.41 | Neutral |
| TRIX (15) | 0.21 | Buy |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 33.27 | Neutral |
| Momentum (10) | -1.16 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 10.08 | Buy |
| ADX (14) | 12.25 | Neutral |
| ATR (14) | 0.60 | Info |
The near-term technical picture is bearish. RSI14 is 40, indicating modest negative momentum, and the price is currently trading near the $10 territory. The 50-day simple moving average is $10.60. A key positional setup shows a support at $8.56 and resistance at $13.25.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.56 | $10.37 | $15.67 | 0% | Neutral | |
| $5.79 | $8.98 | $15.05 | -13% | Neutral | |
| $7.68 | $13.20 | $23.99 | +27% | Bullish | |
| $7.99 | $15.04 | $29.10 | +45% | Bullish | |
| $6.78 | $13.91 | $28.31 | +34% | Bullish | |
| $6.93 | $15.40 | $32.72 | +48% | Bullish | |
| $5.97 | $13.26 | $29.29 | +28% | Bullish | |
| $5.53 | $12.29 | $28.09 | +19% | Neutral | |
| $6.62 | $14.71 | $33.84 | +42% | Bullish | |
| $7.69 | $17.08 | $39.29 | +65% | Bullish | |
| $8.37 | $18.60 | $42.79 | +79% | Bullish | |
| $16.64 | $36.97 | $85.03 | +256% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $8.56 | $10.37 | $12.38 | +0.00% |
| June 2026 | $8.40 | $10.30 | $13.22 | -0.71% |
| July 2026 | $8.89 | $11.18 | $14.89 | +8.63% |
| August 2026 | $8.79 | $11.30 | $15.46 | +1.00% |
| September 2026 | $8.15 | $10.65 | $14.91 | -5.70% |
| October 2026 | $8.13 | $10.79 | $15.40 | +1.32% |
| November 2026 | $8.31 | $11.19 | $16.25 | +3.73% |
| December 2026 | $7.78 | $10.62 | $15.67 | -5.09% |
Click any year to see its month-by-month EIKN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, EIKN could reach as high as $15.67, with a base case around $10.37 and support toward $8.56 — roughly 0% from $10.37. Price action looks broadly range-bound.
Expect EIKN to range from $5.79 to $15.05 through 2027. The $8.98 average target implies a -13% move from current prices. That is -13% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The EIKN price prediction for 2028 points to an average of $13.20 (low $7.68, high $23.99) — a potential gain of +27% on today's $10.37. Momentum favours further upside here.
In 2029, EIKN is projected to trade between $7.99 and $29.10, averaging $15.04 — a potential gain of +45% from today's $10.37. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Eikon Therapeutics, Inc.'s 2030 outlook centres on $13.91, within a $6.78 to $28.31 range. That is -8% versus the projected 2029 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2031, EIKN could reach as high as $32.72, with a base case around $15.40 and support toward $6.93 — roughly +48% from $10.37. Buyers look set to stay in control over this stretch.
Expect EIKN to range from $5.97 to $29.29 through 2032. The $13.26 average target implies a +28% move from current prices. That is -14% versus the projected 2031 average. Momentum favours further upside here.
The EIKN price prediction for 2033 points to an average of $12.29 (low $5.53, high $28.09) — a potential gain of +19% on today's $10.37. A consolidation phase looks the most probable path here.
In 2034, EIKN is projected to trade between $6.62 and $33.84, averaging $14.71 — a potential gain of +42% from today's $10.37. That is up +20% on the projected 2033 average. Momentum favours further upside here.
Eikon Therapeutics, Inc.'s 2035 outlook centres on $17.08, within a $7.69 to $39.29 range. That is up +16% on the projected 2034 average. That marks a +65% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, EIKN could reach as high as $42.79, with a base case around $18.60 and support toward $8.37 — roughly +79% from $10.37. Momentum favours further upside here.
Expect EIKN to range from $16.64 to $85.03 through 2050. The $36.97 average target implies a +256% move from current prices. That is up +99% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in EIKN today (≈ 96.432015 EIKN) could be worth
$3,564.86
+$2,564.86 (+256%) by 2050 · US Dollar
Based on the average projected EIKN price of $36.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EIKNwould be worth at today's price.
$1,000 invested in EIKN on Feb 5, 2026 (≈ 66.666667 EIKN) would be worth
$691.33
-$308.67 (-30.9%) today · 0.69× · US Dollar
Based on a EIKN entry price of $15 vs. today's $10.37.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.66 | $972.8 | -2.7% |
| 1 month ago | $8.74 | $1,186.5 | +18.6% |
| 3 months ago | $13.64 | $760.26 | -24.0% |
| All time ago | $15 | $691.33 | -30.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EIKN forecast.
Our base-case forecast reaches $21.00 around 2050.
Implied market cap at $21.00: $1.14B
The multi-year forecast outlines a path of evolving average prices and ROI across years. For 2026, the average price is $9.90 with an ROI of 0 and neutral sentiment. In 2027, the average price is $8.37 with a negative ROI of -15.5 and bearish sentiment.
The trajectory improves through subsequent years, with 2028 at an average of $12.00 and ROI 21.2 (bullish), 2029 at $13.77 with ROI 39.1 (bullish), and 2030 at $12.90 with ROI 30.3 (bullish). The sequence continues through 2031 at $14.28 (ROI 44.3), 2032 at $12.22 (ROI 23.4), 2033 at $11.22 (ROI 13.3), 2034 at $13.10 (ROI 32.4), and 2035 at $15.16 (ROI 53.1). By 2040 the average price is $16.51 with ROI 66.8 (bullish), and by 2050 the average price is $33.17 with ROI 235 (bullish), with the 2050 max price at $76.28.
These projections show a long-run bullish tilt overall, albeit with periods of volatility and mixed sentiment along the way.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $12.90 with a 30.3% ROI and bullish sentiment.
Forecasts indicate a long-run bullish tilt with 2050 average price of $33.17 and ROI 235%, but there are years with negative or lower returns (e.g., 2027 ROI -15.5). These are estimates, not guarantees.
Yes, the 2050 forecast lists a max price of $76.28, but this is an upper bound in the projection and not guaranteed.
Current price is $9.90 and market cap is $535.97M.
Bearish sentiment with RSI 40. The 30-day range is $6.82 to $14.37, the SMA50 is $10.60, with support at $8.56 and resistance at $13.25.
Eikon Therapeutics, Inc. Community Discussion
0Share your Eikon Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.